U.S. markets closed
  • S&P Futures

    4,163.75
    -12.50 (-0.30%)
     
  • Dow Futures

    33,981.00
    -100.00 (-0.29%)
     
  • Nasdaq Futures

    13,992.75
    -36.75 (-0.26%)
     
  • Russell 2000 Futures

    2,248.50
    -10.50 (-0.46%)
     
  • Crude Oil

    62.82
    -0.31 (-0.49%)
     
  • Gold

    1,778.90
    -1.30 (-0.07%)
     
  • Silver

    26.03
    -0.07 (-0.27%)
     
  • EUR/USD

    1.1973
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3824
    -0.0015 (-0.11%)
     
  • USD/JPY

    108.7220
    -0.0610 (-0.06%)
     
  • BTC-USD

    56,126.41
    -4,848.30 (-7.95%)
     
  • CMC Crypto 200

    1,267.29
    -124.42 (-8.94%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,544.30
    -139.07 (-0.47%)
     

Moderna Proposes Filling Vials With Additional Doses Of COVID-19 Vaccine - Reuters

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • As Moderna Inc (NASDAQ: MRNA) approaches to manufacture almost one million doses a day, the company has proposed filling COVID-19 vaccine vials with additional doses of up to 15 versus 10 currently to ease the manufacturing crunch, Reuters reports.

  • Last week CNBC reported that Moderna had asked the FDA to fill its COVID-19 vaccine vials with up to five additional doses.

  • “Additional doses would help address capacity constraints, noting that “beyond the amount of drug product available, is how many vials you can fill in a given period of time,” said Moderna’s President, Stephen Hoge.

  • “Moderna would need to have further discussions with the FDA to assure the agency’s comfort with this approach before implementing,” the company said.

  • Yesterday, BofA Securities’ analyst downgraded the company’s stock from Neutral to Underperform and maintained a $150 price target, citing that MRNA shares have increased to difficult levels to justify a fundamental basis.

  • Price Action: MRNA shares are higher by 2.15% at $160.86 in the pre-market session on the last check Tuesday. 

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.